Imunon, Inc. 8-K

What Happened

• Imunon reported that interim Chief Financial Officer Jeffrey Church informed the company on June 29, 2026 of his intent to retire, effective July 1, 2026. To support a smooth handover, Mr. Church will continue in a consulting role under an amended consulting agreement paying him a $10,000 monthly retainer (terminable on two business days' notice). The company stated his departure is due to retirement and is without any disagreements with management.
• Effective July 1, 2026, Imunon appointed Josh Blacher (age 54) as its new interim Chief Financial Officer and principal accounting officer under a master services agreement dated June 24, 2026 with Danforth Health, Inc. Danforth will bill the company $475 per hour for Mr. Blacher’s CFO services. Mr. Blacher is a finance consultant with prior CFO roles at several life sciences companies and holds a BA in Economics (Yeshiva) and an MBA in Finance (Columbia).

Key Details

• Jeffrey Church’s retirement effective date: July 1, 2026; he will transition to a consulting role.
• Consulting retainer for Mr. Church: $10,000 per month, terminable on two business days' notice.
• New interim CFO: Josh Blacher, appointed July 1, 2026 under master services agreement with Danforth Health, Inc. (dated June 24, 2026).
• Fee for Blacher’s services: $475 per hour billed to Imunon by Danforth; agreement filed as Exhibit 10.1 to the 8‑K.

Why It Matters

• A CFO change affects the company's financial leadership and may impact reporting, controls and investor communications; Imunon has put in place continuity measures (consulting arrangement with the departing CFO and an experienced outsourced CFO).
• The arrangement introduces ongoing consulting/contract costs (monthly retainer and hourly billing) that investors may want to monitor. The company disclosed no disagreements with Mr. Church and no related-party interests for Mr. Blacher. The master services agreement is available as an exhibit for review.